Physician profile
Aaron T Sharp
NPI 1215432935
$5,649.58
in general payments reported to CMS, 2019-2025
24 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.71 · 2022: $687 · 2023: $1,746 · 2024: $1,698 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,160.16 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $723.16 | 2022-2025 | |
| Novo Nordisk INC | $681.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $315.66 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.60 | 2022-2023 | Jardiance |
| Lilly USA, LLC | $217.08 | 2023-2025 | Mounjaro |
| Exact Sciences Corporation | $205.26 | 2023-2025 | Cologuard Collection Kit |
| Stryker Corporation | $173.77 | 2025 | Mako |
| Medtronic, INC. | $117.20 | 2024 | Corevalve Evolut R |
| Silk Road Medical, INC. | $115.53 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Edwards Lifesciences Corporation | $103.94 | 2022 | |
| Pfizer INC. | $103.43 | 2023-2025 | |
| Glaxosmithkline, LLC. | $93.99 | 2021-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $90.37 | 2022-2023 | Gattex |
| Shield Therapeutics INC | $74.67 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $39.02 | 2025 | Cequr Simplicity |
| Dexcom, INC. | $30.45 | 2022-2023 | Dexcom G6 Transmitter |
| Ethicon US, LLC | $28.21 | 2022 | |
| Noven Therapeutics, LLC | $24.14 | 2024 | Xelstrym |
| Sanofi-Aventis U.S. LLC | $22.82 | 2023 | |
| Alnylam Pharmaceuticals INC. | $20.74 | 2023 | Givlaari |
| Inspire Medical Systems, INC. | $19.89 | 2024 | Inspire |
| Aimmune Therapeutics, INC. | $19.13 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.32 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.